importance of the T-stage and have reanalyzed our primary data. By analysis of variance and the Wilcoxon rank sum test, we show that the distribution of maximum standardized uptake value (SUV max ) within the three "T" groups (T1a/T1b/T2a) is significantly different (p < 0.0001). Cox proportional hazards model was then used to assess the relationship between T-stage and survival with and without adjustment for SUV max (uncategorized). After adjustment for T-stage, the effect of SUV max remains statistically significant (p = 0.003). In our study, the effect of T-stage was not a statistically significant predictor of survival with or without adjustment for SUV max . The lack of statistical significance for T-stage does not necessarily imply that the variable does not have prognostic importance. Rather, the power of this statistical analysis may be limited by there being only 134 deaths, which in general drives the power of a study to detect a clinically meaningful effect.
As we suggested, prospective treatment trials in early-stage disease could incorporate SUV max to stratify patients for therapy, although we acknowledge that other features including T-stage need to be considered. Reply to "Prognostic Value of FluorodeoxyglucosePositron Emission Tomography"
Woocheol Kwon, MD
To the Editor: I read with interest the elegant study by Kwon et al 1 in which the authors demonstrated a significant correlation between survival and fluorodeoxyglucose (FDG) uptake on positron emission tomography in stage I non-small-cell lung cancer (NSCLC) patients. However, I found it surprising that tumor size, as reflected in the "T" classification (e.g., T1 versus T2a, or T1a versus T1b versus T2a), was not taken into account in the multivariate analysis of potential prognostic factors.
In the Discussion section, 1 among their study limitations, the authors correctly mention the fact that FDG uptake can be underestimated in small tumors (e.g., <2 cm) because of "volume averaging effects inherent in positron emission tomography." However, they fail to infer that this limitation could explain in part (if not all) their findings. I note that 36% of the study population (122 out of 336 patients) had T1aN0 tumors, and 40% of the study population (134 patients) had T2aN0 tumors.
Therefore, I wonder if the prognostic value attributed to FDG uptake could be in fact a mere tumor size effect as, by definition, tumor size reflected in the T classification is a strong and well-characterized prognostic factor in early-stage NSCLC. 2 Could the authors provide their study results after introducing the T classification in the multivariate analysis, and/or explain why they chose not to do so? Without such 
